Compare Autodesk Inc (ADSK) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.

Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.

AMLX trades at $17.97, down 1.64% today, with strong analyst support showing 91% buy ratings and a $30.50 consensus price target representing 70% upside potential. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest some overbought conditions. Recent earnings showed mixed results with a Q1 2026 miss after two previous beats, while the company continues advancing its pipeline with Phase 3 data for avexitide expected in Q3 2026.

Despite negative profitability metrics and cash burn, AMLX maintains strong institutional confidence with 11 analysts covering the stock. The key catalyst remains the upcoming Phase 3 avexitide readout, though risks include ongoing class action litigation and the company's negative cash flow from operations. Current valuation at 7.31x book value reflects optimism around pipeline assets rather than current financial performance.